Table 3 Quality of life as assessed on the St George's Hospital Respiratory
From: Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease
| Â | Losartan | Placebo | Â | ||||
|---|---|---|---|---|---|---|---|
| Â | Baseline (n = 19) | End of study (n = 15) | Change | Baseline (n = 20) | End of study (n = 18) | Change | p-value* |
Overall score | 66 (18) | 60 (15) | -3.6 (9.2) | 65 (14) | 66 (19) | +1.7 (9.2) | 0.11 |
Symptom component | 72 (17) | 67 (22) | -2.7 (15.5) | 71 (16) | 66 (20) | -5.6 (16.3) | 0.61 |
Activity component | 76 (17) | 74 (13) | -1.2 (10.8) | 77 (17) | 83 (19) | +7.5 (14.1) | 0.06 |
Impact component | 57 (23) | 49 (18) | -5.2 (12.6) | 56 (17) | 56 (22) | +0.7 (13.1) | 0.20 |